Business Context and Reporting Period
This Form 8-K Current Report from Inmune Bio, Inc. (INMB) covers events occurring on November 18, 2025. The filing primarily details the results of a Special Meeting of Stockholders held on this date to approve a one-time repricing of outstanding stock options and announces upcoming clinical trial presentations.
Key Financial Metrics
This filing is a current report regarding corporate governance and events; it does not contain audited financial statements, revenue, profit, cash flow, or debt metrics. The only financial data points provided are:
- Stock Price: $1.50 per share (Closing price on November 18, 2025, used as the new exercise price).
- Shares Outstanding (Record Date): 26,585,258 shares as of September 30, 2025.
- Shares Voted: 10,193,242 shares present or represented at the Special Meeting.
Material Changes and Corporate Actions
Option Repricing Approval
Stockholders approved a one-time repricing of eligible stock options covering up to 5,511,000 shares. Effective November 18, 2025, the exercise price for these options was automatically reduced to $1.50 per share, matching the closing market price on the Repricing Date. This action applies to options held by employees, executive officers, and Board members under the Company's 2017, 2019, and 2021 Stock Incentive Plans.
Voting Results
| Proposal | For | Against | Abstentions |
|---|---|---|---|
| Option Repricing (Proposal 1) | 7,144,433 | 2,926,973 | 121,836 |
| Adjournment (Proposal 2) | 7,279,350 | 2,866,941 | 46,951 |
Outlook, Risks, and Other Events
Clinical Updates: The Company announced two presentations scheduled for the 18th Clinical Trials on Alzheimer's Disease conference in San Diego, CA, from December 1-4, 2025. Details are contained in the press release filed as Exhibit 99.1.
Risks and Contingencies: The filing does not explicitly list new risk factors or contingencies beyond the standard implications of stock option repricing, which may impact future dilution and compensation expenses.
Investor Verification Checklist
- Verify the specific impact of the option repricing on future dilution and share count.
- Review the content of the press release (Exhibit 99.1) for details on the Alzheimer's Disease conference presentations.
- Monitor the Company's cash burn rate and liquidity position in subsequent filings (10-Q/10-K), as this 8-K does not provide current financial health data.
- Confirm the vesting schedules and terms of the repriced options to understand future compensation obligations.